18/12/2025 15:57
Morgan Stanley lowered the target price for CSPC Pharma (01093) to HKD10.4 from HKD11 and maintained the "overweight" rating.
The research house said it now projects sales and recurring net profit growth of +5% and +7% in 2026, accelerating to +6% and +10% in 2027, respectively, as new product launches gain traction.
【你點睇？】美、烏、歐多方在柏林會晤商討俄烏和談，你認為本輪磋商會否取得階段性成果？► 立即投票
上一篇新聞︰19/12/2025 14:33 {I-bank focus}Jefferies lowers Xiaomi (01810) to HKD43.36
下一篇新聞︰16/12/2025 16:08 {I-bank focus}Citi raises China Shenhua (01088) to HKD45.1
16/12/2025 14:43 {I-bank focus}Morgan lowers ZTE (00763) to HKD31.5
15/12/2025 16:00 {I-bank focus}Citi raises Li Ning (02331) to HKD20.6
15/12/2025 14:35 {I-bank focus}Morgan raises Ali Health (00241) to HKD4.6
